RB1 and neoplasm: For instance, recent pre-clinical studies in pancreatic adenocarcinoma suggest that CDK4/6 inhibitors should be administered after (not before) cytotoxic chemotherapeutics since activation of RB1 represses the DNA repair machinery and enhances DNA damage-induced tumor cell death [216].